Aspen Neuroscience, a Phase 1/2a biotech developing stem cell therapies for Parkinson’s disease, announced terms for its IPO ...

LIS Technologies, which develops laser-based uranium enrichment technologies for nuclear energy, filed on Monday with the SEC ...

Lycia Therapeutics, a Phase 1 biotech developing protein degraders for food allergy and Graves' disease, raised $318 million ...

Africa-linked IPOs are having a strong year. Seven companies with significant African operations have raised at least $100 ...

Windward Bio Group, a Switzerland-based Phase 2/3 biotech developing antibodies for respiratory and dermatologic diseases, filed on Friday with the SEC to raise up to $100 million in an initial public ...

Rezera, a Phase 3-ready biotech developing oral NLRP3 inhibitors for inflammatory diseases, filed on Wednesday with the SEC to raise up to $100 million in an initial public offering.Rezera is ...

This week’s big news: what didn’t happen. No public filing from Anthropic as fresh volatility gripped AI stocks. We’ve been here before. New stocks are volatile, and while we can’t predict when growth ...

International IPO Index: International markets traded off further this week, amid global AI worries. The International IPO Index plunged -4.1%, while the ACWX ex-US ETF traded down -1.0%.

Rezera, a Phase 3-ready biotech developing oral NLRP3 inhibitors for inflammatory diseases, filed on Wednesday with the SEC for an initial public offering. The company's filing included a placeholder ...

BHAV Acquisition II, a blank check company targeting robotics, EVs, fintech, advanced computing and energy tech, lowered the proposed deal size for its upcoming IPO on Friday. The Piscataway, NJ-based ...

Three IPOs are currently scheduled for the week ahead as investors continue to hold their breath for the year’s last potential mega IPO. Africa-focused digital bank and fintech platform OPay (OPAY) ...